CIK: 0001616824
Total reported value
$155.8M
Reporting period: 2026-03-31 · Number of holdings: 16
BML Capital Management, LLC disclosed 16 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $155.8M and a quarterly turnover rate of 36.3%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "B"
BML Capital Management, LLC's disclosed holdings carry a Herfindahl concentration index of 0.195 — mathematically equivalent to about 5 equally-sized positions, well below its 16 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 1.50), with a handful of outsized bets alongside many smaller positions.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 9% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add OM
+250.2% $5.3M
Trim ACRS
0.0% $10.5M
Trim TIL
0.0% -$1.8M
Trim PMVP
+0.5% -$18.2K
Add AVIR
-5.8% $11.2M
Trim KMX
0.0% $455.7K
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACRS | Aclaris Therapeutics INC | Stock-Other | 34.31% | -2.77% | — | |
| 2 | AVIR | Atea Pharmaceuticals INC | Stock-Other | 24.38% | +1.27% | -5.76% | |
| 3 | ORMP | Oramed Pharmaceuticals INC | Stock-Other | 6.91% | -0.89% | — | |
| 4 | TLYS | Tilly's Inc-class A Shrs | Stock-Other | 5.59% | +5.59% | NEW | |
| 5 | OM | Outset Medical INC | Stock-Other | 4.69% | +2.95% | +250.20% | |
| 6 | PMVP | Pmv Pharmaceuticals INC | Stock-Other | 4.24% | -1.48% | +0.53% | |
| 7 | KMX | Carmax INC | Stock-Consumer Disc | 4.14% | -1.04% | — | |
| 8 | 2KZ0 | Kezar Life Sciences INC | Stock-Other | 3.43% | -0.49% | — | |
| 9 | TIL | Instil Bio INC | Stock-Other | 3.42% | -2.72% | — | |
| 10 | TGT | Target CORP | Stock-Consumer Disc | 2.92% | -0.25% | — | |
| 11 | KHC | Kraft Heinz Co/the | Stock-Consumer Staples | 1.80% | +1.80% | NEW | |
| 12 | JANX | Janux Therapeutics INC | Stock-Other | 1.38% | +1.38% | NEW | |
| 13 | PLRX | Pliant Therapeutics INC | Stock-Other | 1.25% | -0.38% | — | |
| 14 | ✓ | Connect Biopharma Hldgs LTD | Stock-Other | 0.69% | -0.31% | — | |
| 15 | IMA | Imagenebio INC | Stock-Other | 0.64% | -0.42% | +13.39% | |
| 16 | WMT | Walmart INC | Stock-Consumer Staples | 0.21% | -0.22% | — |
Performance for Q3 2026
+14.4%
Performance Last 4 Quarters
+151.7%
Based on 71% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 16 | $155.8M | 36 | |
| 2025-12-31 | 16 | $115.7M | 62 | |
| 2025-09-30 | 20 | $109.2M | 61 | |
| 2025-06-30 | 24 | $132.2M | 0 | |
| 2025-03-31 | 27 | $123.6M | 0 | |
| 2024-12-31 | 25 | $161.0M | 0 | |
| 2024-09-30 | 29 | $169.9M | 0 | |
| 2024-06-30 | 28 | $140.1M | 0 | |
| 2024-03-31 | 32 | $151.7M | 0 | |
| 2023-12-31 | 35 | $132.0M | 0 | |
| 2023-09-30 | 26 | $108.9M | 0 | |
| 2023-06-30 | 31 | $111.2M | 0 | |
| 2023-03-31 | 31 | $115.7M | 0 | |
| 2022-12-31 | 25 | $104.7M | 0 |
BML Capital Management, LLC's most significant position changes for 2026-03-31: New buy: Tilly's Inc-class A Shrs (TLYS); New buy: Kraft Heinz Co/the (KHC); New buy: Janux Therapeutics INC (JANX); Sold out: Carvana Co (CVNA); Sold out: Tesla INC (TSLA).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | OM | Outset Medical INC | +3% | +250.20% | Add |
| 2 | AVIR | Atea Pharmaceuticals INC | +1.3% | -5.76% | Trim |
| 3 | WMT | Walmart INC | -0.2% | — | Unchanged |
| 4 | TGT | Target CORP | -0.3% | — | Unchanged |
| 5 | ✓ | Connect Biopharma Hldgs LTD | -0.3% | — | Unchanged |
| 6 | PLRX | Pliant Therapeutics INC | -0.4% | — | Unchanged |
| 7 | IMA | Imagenebio INC | -0.4% | +13.39% | Add |
| 8 | 2KZ0 | Kezar Life Sciences INC | -0.5% | — | Unchanged |
| 9 | ORMP | Oramed Pharmaceuticals INC | -0.9% | — | Unchanged |
| 10 | KMX | Carmax INC | -1% | — | Unchanged |
| 11 | PMVP | Pmv Pharmaceuticals INC | -1.5% | +0.53% | Add |
| 12 | TIL | Instil Bio INC | -2.7% | — | Unchanged |
| 13 | ACRS | Aclaris Therapeutics INC | -2.8% | — | Unchanged |
| 14 | TLYS | Tilly's Inc-class A Shrs | — | NEW | New buy |
| 15 | KHC | Kraft Heinz Co/the | — | NEW | New buy |
| 16 | JANX | Janux Therapeutics INC | — | NEW | New buy |
| 17 | CVNA | Carvana Co | — | EXIT | Sold out |
| 18 | TSLA | Tesla INC | — | EXIT | Sold out |
| 19 | LSTA | Lisata Therapeutics INC | — | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-06 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-03 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-10 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-11 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-07 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-07 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-05 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-07 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-04-24 | Amendment | View on EDGAR |
| 2024-03-31 | 2024-04-23 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-02 | Amendment | View on EDGAR |
| 2023-12-31 | 2024-01-30 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-10-23 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-07-24 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-04-14 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-13 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0002028621
Total reported value
$155.8M
77 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0002111175
Total reported value
$155.8M
90 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001721168
Total reported value
$155.7M
32 stks
2026-03-31
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0001543065
Total reported value
$10.5M
27 stks
2023-09-30
Stale — no recent filing
1 of the top 5 holdings overlap, including Atea Pharmaceuticals INC
CIK 0001559565
Total reported value
$183.2M
8 stks
2017-12-31
Stale — no recent filing
1 of the top 5 holdings overlap, including Aclaris Therapeutics INC
CIK 0002010850
Total reported value
$661.3M
14 stks
2026-03-31
1 of the top 5 holdings overlap, including Aclaris Therapeutics INC